Skip to main content

Dorval Allison's Form 4 filing

Verve Therapeutics, Inc. (VERV) · filed Dec 1, 2023

Accession no.
0000950170-23-067358
Filed
Dec 1, 2023
Trade date
Nov 29, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.34K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dorval AllisonCIK 0001625110Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 29, 2023Common StockMOption exerciseAcquired+1,875–F1–4,614Direct
Nov 29, 2023Common StockSSaleDisposed−554$11.45−$6,343.34,060Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 29, 2023Common StockMOption exerciseDisposed−1,875$0.00$03,750Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)